hotspot -WSS

hotspot

author：entertainment 2025-09-30 00:03:04 - browse：3685

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Coloradans with cystic fibrosis could lose access to Trikafta

hotspot

WSS

Gene therapy’s promise and the high cost of hope

Here’s what’s in the FDA plan to include pregnant women in clinical trials

The health care issue Democrats can’t solve: hospital reform

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Coloradans with cystic fibrosis could lose access to Trikafta

leisure time

hotspot

knowledge

The high cost of giving birth even with insurance

Having children helps parents live longer, especially after age 80

How one medical school became remarkably diverse

Congress might make insulin pumps more accessible to the blind

Sports medicine is finally prioritizing gender equality

Artificial intelligence use in health care faces greater scrutiny in 2024

Drug repurposing or repositioning? The language matters

Why Eli Lilly’s earnings didn’t quite live up to the hype

Jerome Adams on the need for new antivirals for Covid

Resistance to opioid

focus

How to convince healthy people to buy insurance

Brain injuries and the importance of a second opinion

How to convince healthy people to buy insurance

Explaining an after

All of Us, NIH's precision medicine initiative, gets a big boost

Juul documents reveal insider tactics on political lobbying

entertainment

hotspot

hotspot

focus